SenesTech Inc 2026年季度报告

FORM 10-Q For the quarterly period ended March 31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37941 SENESTECH, INC.(Exact name of registrant as specified in its charter) (928) 779-4143(Registrant’s telephone number, including area code) N/A(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registered Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filerEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo The number of shares of common stock outstanding as of May11, 2026: 5,303,426 SENESTECH, INC.FORM 10-QFOR THE QUARTERLY PERIOD ENDED MARCH 31, 2026 TABLE OF CONTENTS PART I — FINANCIAL INFORMATIONItem 1.Financial Statements (unaudited)1Condensed Balance Sheets1Condensed Statements of Operations and Comprehensive Loss2Condensed Statements of Cash Flows3Notes to Condensed Financial Statements4Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations14Item 3.Quantitative and Qualitative Disclosures About Market Risk20Item 4.Controls and Procedures20PART II — OTHER INFORMATIONItem 1.Legal Proceedings21Item 1A.Risk Factors21Item 5.Other Information21Item 6.Exhibits21SIGNATURES22 PART I — FINANCIAL INFORMATION SENESTECH, INC.CONDENSED BALANCE SHEETS(In thousands, except shares and per share data) SENESTECH, INC.CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(In thousands, except shares and per share data)(Unaudited) SENESTECH, INC.CONDENSED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited) SENESTECH, INC.NOTES TO CONDENSED FINANCIAL STATEMENTS(Unaudited) NOTE 1: BASIS OF PRESENTATION Nature of Business SenesTech, Inc. (subsequently referred to in this report as “we,” “us,” “our,” or “our company”) was incorporated in the state ofNevada in July 2004. In November 2015, we subsequently reincorporated in the state of Delaware. Our corporate headquarters andmanufacturing site are in Surprise, Arizona. We have developed and are commercializing products for managing animal pestpopulations through fertility control. Our current products focus on rat and mouse populations, and are known as ContraPest , EvolveRat and Evolve Mouse.®® CONTRAPEST. ContraPest, our initial product, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide andtriptolide. ContraPest targets the reproductive systems of both male and female rats, is a highly palatable formulation, does not causeillness or changed behavior in rats, and leads to significant reductions in fertility and rat populations. Accordingly, ContraPest is anadditional tool to use as part of an integrated pest management program. ContraPest is registered in all 50 states and the District of Columbia (49 states and the District of Columbia have approved therestricted use pesticide designation) and two major U.S. territories, Puerto Rico and the U.S. Virgin Islands. EVOLVE. The Evolve product line, which began in the form of Evolve Rat, launched in January 2024, and is currently our leadproduct. Evolve Rat is a soft bait product that is novel to the pest control industry and contains the active ingredient, cottonseed oil.Evolve Rat reduces fertility in both male and female rats. Additionally, its palatable formulation produces high acceptance forsustained consumption even when other sought-after food sources are present. Evolve Rat does not cause illness in rats and, therefore,it does not change behavior or resul